Exploration of the Impact of Preferred Drug Lists on Hospital and Physician Visits and the Costs to Medicaid
Can Medicare Sustain Widespread Access to GLP-1 Therapies?
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
AJMC® in the Press, April 25, 2025
Trump Tariffs on Pharmaceuticals Risk Causing Higher Costs, Drug Shortages